Exelixis Q2 Revenue Falls 11 Percent

Exelixis (NASDAQ:EXEL) reported mixed Q2 FY2025 results, with non-GAAP EPS of $0.75 beating expectations, while GAAP revenue of $568.3 million declined 10.8% year-over-year and slightly missed estimates, primarily due to the absence of a $150 million collaboration milestone recorded in Q2 2024. Despite this, net product revenue, largely from CABOMETYX, rose 18.8% year-over-year, reflecting strong underlying product demand, further supported by recent U.S. and European approvals for CABOMETYX in neuroendocrine tumors and patent litigation resolution extending its U.S. patent protection until at least 2031. Additionally, pipeline advancements, notably positive Phase 3 results for zanzalintinib in colorectal cancer, reinforce Exelixis' strategy to diversify its oncology portfolio and drive future growth beyond its current cabozantinib reliance.

Analysis

Exelixis reported mixed Q2 FY2025 results, with a non-GAAP EPS of $0.75 that surpassed consensus estimates, juxtaposed with a GAAP revenue of $568.3 million that declined 10.8% year-over-year and missed forecasts. This revenue shortfall, however, is not indicative of core business weakness but is entirely attributable to the absence of a non-recurring $150.0 million collaboration milestone payment that was present in Q2 2024. The underlying commercial performance remains robust, evidenced by an 18.8% year-over-year increase in net product revenue to $520.0 million, driven by strong demand for its flagship therapy, CABOMETYX. The company's strategic position was significantly strengthened by two key developments: a litigation settlement that extends U.S. patent protection for cabozantinib to at least 2031, and positive Phase 3 data for zanzalintinib in colorectal cancer, which represents a critical step toward diversifying revenue beyond CABOMETYX. Management's confidence is further signaled by the maintenance of full-year 2025 guidance and a substantial share repurchase program that has reduced the share count by over 13% since March 2023.

Key Decisions for Investors

• Investors should look past the headline GAAP revenue miss, which was distorted by milestone timing, and instead focus on the 18.8% growth in net product revenue as the key indicator of underlying business health.
• The positive Phase 3 data for zanzalintinib is a significant de-risking event; monitor upcoming regulatory submission timelines as this asset is crucial for the company's long-term revenue diversification and reducing its reliance on CABOMETYX.
• Consider the extended patent protection for CABOMETYX until 2031 and the aggressive share buybacks as strong positive signals, while remaining cognizant of the concentration risk associated with having over 90% of product sales tied to a single drug.
• Track the sales ramp from the newly approved neuroendocrine tumor (NET) indication, as successful commercial execution here will provide further evidence of the company's ability to expand its market and drive organic growth.